Manuel D. G.
- Country
- Spain
- Department
- Oncology
Research Overview
- A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab, with or without Platinum Chemotherapy, in Subjects with No Prior Therapy for Advanced or Metastatic PD-L1 TPS<50% Non-squamous Non-small Cell Lung Cancer without Actionable Genomic Alterations (TROPION-Lung07)
- A Comparative Study of ABP 234 and Pembrolizumab in Patients with Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
- Phase 2 Open‑Label Multicohort Study of Rinatabart Sesutecan Monotherapy in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer
Data & Insights
Has run more than one trial at 349 of 588 partner sites.
Specializations
Hematologic Malignancies
The investigator concentrates on blood‑derived cancers that often present with aggressive clinical courses and limited treatment options.
- Acute myeloid leukemia
- Myelodysplastic syndrome
- Chronic lymphocytic leukemia
- Diffuse large B‑cell lymphoma
- Peripheral T‑cell lymphoma
Research efforts target refractory disease states and measurable residual disease eradication at Hospital Universitario Fundación Jiménez Díaz, Madrid.
Solid Tumor Oncology
Broad activity across major solid malignancies drives the investigator’s clinical portfolio.
- Non‑small cell lung cancer
- Metastatic colorectal cancer
- Advanced breast cancer
- Renal cell carcinoma
- Hepatocellular carcinoma
Trials span first‑line to late‑stage settings, emphasizing efficacy in high‑risk and metastatic disease.
Targeted Molecular Oncology
Precision medicine approaches focus on cancers defined by actionable genetic alterations.
- KRAS‑mutated tumors
- EGFR‑mutant NSCLC
- HER2‑positive breast cancer
- ALK‑positive lung cancer
- IDH1‑mutated AML
Enrollment criteria prioritize biomarker‑driven selection to match targeted agents with molecular profiles.
Immunotherapy and Biomarker‑Driven Trials
Immune‑modulating strategies are applied to malignancies with defined immune signatures.
- PD‑L1‑positive NSCLC
- CTLA‑4 blockade
- CAR‑T therapy for B‑cell malignancies
- Checkpoint inhibitor combinations
- Tumor mutational burden‑guided studies
These programs integrate novel immunologic agents with conventional chemotherapy across multiple tumor types.
Non‑Oncologic Therapeutic Interests
Beyond cancer, the investigator engages in clinical research addressing chronic and acute systemic diseases.
- Chronic kidney disease
- Severe asthma
- Autosomal dominant polycystic kidney disease
- Acute respiratory distress syndrome
- Cardiovascular disease
Collaborative studies aim to improve outcomes in organ‑specific dysfunction and inflammatory conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.